journal article·2025-03-26

Chirality-Controlled Lipid Nanoparticles for mRNA Delivery

Juhee Lee, Wookjin Jung, Dongkyu Lee, Mihyun Kang, Hyun Jung Chung, Jihyeon Yeom

ACS Applied Materials & Interfaces· Volume 17· Issue 12
Publisher page

Abstract

mRNA therapeutics present a promising strategy for the treatment of human diseases, which requires a carrier to protect the mRNA and ensure its effective cellular delivery. However, research on how the surface physicochemical properties of the mRNA carriers affect the efficiency of delivery of mRNA into cells has been limited thus far. Here, we report that chirality control of lipid nanoparticles (LNPs) can enhance the delivery and transfection efficiency of cargo mRNA into cells. We prepared chiral LNPs by surface modification of LNPs with chiral cobalt oxide nanoparticles. The chiral LNPs with d- or l-chirality resulted in different cellular uptake and transfection efficiencies of luciferase or EGFP mRNA. Chiral LNPs with d-chirality showed significant enhancement in cellular delivery as well as transfection (5.3-fold) of mRNA compared to the control LNPs. This study suggests a novel strategy of using chirality for the delivery of nucleic acid drugs and provides a more in-depth understanding of the effect of chirality on cells.
Source: openalex_inverted_index · Quality: baseline

Research context

OpenAlex topics: RNA Interference and Gene Delivery · Advanced biosensing and bioanalysis techniques · Lipid Membrane Structure and Behavior

SciVX discovery tags are terminology-based. OpenAlex topics are source-provided classifications.

Affiliations

Department of Biological Sciences

Korea Advanced Institute of Science and Technology

Department of Materials Science and Engineering

Funding

Ministry of Science and ICT, South Korea · National Research Foundation of Korea

References (39)

Show source-provided references
1. 10.1038/s41587-022-01294-210.1038/s41587-022-01294-2 ↗
2. 10.1186/s12943-021-01348-010.1186/s12943-021-01348-0 ↗
3. 10.1038/s41576-020-0258-410.1038/s41576-020-0258-4 ↗
4. 10.1016/j.addr.2023.11502610.1016/j.addr.2023.115026 ↗
5. 10.1038/nrd.2017.24310.1038/nrd.2017.243 ↗
6. 10.1038/s41392-022-01007-w10.1038/s41392-022-01007-w ↗
7. 10.1016/j.tibtech.2020.06.00210.1016/j.tibtech.2020.06.002 ↗
8. 10.1038/s12276-020-0407-z10.1038/s12276-020-0407-z ↗
9. 10.1038/s41467-022-28776-w10.1038/s41467-022-28776-w ↗
10. 10.1007/s40290-021-00417-510.1007/s40290-021-00417-5 ↗
11. 10.1038/s41578-021-00358-010.1038/s41578-021-00358-0 ↗
12. 10.1002/adtp.20200009910.1002/adtp.202000099 ↗
13. 10.1021/jacs.1c0581310.1021/jacs.1c05813 ↗
14. 10.1016/j.jconrel.2023.08.05310.1016/j.jconrel.2023.08.053 ↗
15. 10.1016/j.ijpharm.2021.12058610.1016/j.ijpharm.2021.120586 ↗
16. 10.1038/s12276-023-01086-x10.1038/s12276-023-01086-x ↗
17. 10.1016/j.isci.2021.10347910.1016/j.isci.2021.103479 ↗
18. 10.1039/D1NR06858J10.1039/D1NR06858J ↗
19. 10.1002/jgm.364210.1002/jgm.3642 ↗
20. 10.1021/acsnano.1c0499610.1021/acsnano.1c04996 ↗
21. 10.1186/s12951-024-02919-110.1186/s12951-024-02919-1 ↗
22. 10.1038/s41467-024-53914-x10.1038/s41467-024-53914-x ↗
23. 10.1038/s41565-022-01071-x10.1038/s41565-022-01071-x ↗
24. 10.1038/s41576-021-00439-410.1038/s41576-021-00439-4 ↗
25. 10.2174/15680261179516509810.2174/156802611795165098 ↗
26. 10.1039/D0CS00093K10.1039/D0CS00093K ↗
27. 10.1038/s41467-017-02268-810.1038/s41467-017-02268-8 ↗
28. 10.1038/s41578-023-00561-110.1038/s41578-023-00561-1 ↗
29. 10.1186/s12951-021-00965-710.1186/s12951-021-00965-7 ↗
30. 10.1126/science.aao717210.1126/science.aao7172 ↗
31. 10.1002/adma.20190387810.1002/adma.201903878 ↗
32. 10.1002/anie.20230707610.1002/anie.202307076 ↗
33. 10.1002/adma.20210935410.1002/adma.202109354 ↗
34. 10.1021/acsami.2c1159610.1021/acsami.2c11596 ↗
35. Lide D. R. · 2004
36. 10.1038/mt.2010.8510.1038/mt.2010.85 ↗
37. 10.1073/pnas.92.14.633410.1073/pnas.92.14.6334 ↗
38. 10.1110/ps.9.7.128210.1110/ps.9.7.1282 ↗
39. 10.1021/acs.molpharmaceut.3c0008910.1021/acs.molpharmaceut.3c00089 ↗